Q4 23: destocking noise offsets recovery in other key segments
08/02/24 -"Novozymes reported a mixed set of Q4 23 numbers, missing at the top line but beating on the bottom line. While the innovation-driven momentum in BioEnergy was complemented by an encouraging recovery ..."
Pages
55
Language
English
Published on
08/02/24
You may also be interested by these reports :
12/11/26
The Q3 results exceeded consensus estimates, backed by the strong showing of Electronics (driven by demand from AI applications) and healthy support ...
11/11/26
The Q3 profitability materially surpassed expectations, backed by the strong momentum for migraine and depression/schizophrenia treatments. The ...
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...